Bayer AG, Pfizer Inc., and F. Hoffmann-la Roche Ltd.– Notable Market Participants in Hemophilia Treatments Industry
Hemophilia treatments refers to surgical supplies that helps to control blood loss and consists of hemophilia treatment agents present in the form of pads, sponges, patches, powders, liquids or others. Factors such as increasing number of surgical procedures, increasing incidence of sports injuries and technological advancements in hemophilia treatments are expected to account for the growth of the market.
The most notable market participants are Bayer AG, Sanofi, F. Hoffmann-la Roche Ltd.,Kedrion S.P.A.,CSL Limited, Biotest AG,Pfizer Inc., Novo Nordisk A/S, Octapharma AG,Baxter International Inc occupying a considerable share of the market owing to their offerings to the market.
Market leaders are involved in inorganic activities such as partnerships and acquisitions in order to improve their performance and consolidate market position. For instance, in March 2018, Sanofi has completed the acquisition with Bioverativ Inc., This acquisition is likely to provide a strong position in the large and growing hemophilia market and expands our presence in specialty care
Prominent players in hemophilia treatments market are also focusing on organic strategies such as product launch, product approval, geographic and manufacturing expansion, and others. These strategies are helping major players to strengthen their market positions along with widening their geographic footprints. Additionally, various companies are also undergoing other strategic alliances such as acquisitions and others to garner their significance and remain competitive in the market. Few of the important key developments from the industry are mentioned below:
|
Year |
News |
Region |
|
2019 |
Roche launched its product Emicizumab under the brand name Hemlibra in India for preventive treatment of Haemophilia A, an inherited disorder in which a person’s blood does not clot properly. |
North America |
|
2018 |
Bayer AG, received US Food and Drug Administration (FDA) approval for its product Jivi, this product is likely to decrease the effect of hemophilia.
|
Asia Pacific |
|
2020 |
Novo Nordisk launched an antihemophilic product nmaely Esperoct. This product is likely to reduce the effect of hemophilia in adults and children with hemophilia A.
|
North America |
